Stock Quote        
  Join        Login  
logo

Cardinal Health (CAH) 4Q Earnings Rise 14 Pct, Yet Guides 2013 Below Street

 August 02, 2012 08:04 AM
 

(By Balaseshan) Cardinal Health Inc. (NYSE:CAH) reported a 14% increase in quarterly earnings on strong segments growth despite flat revenue. Despite results exceeding Street's expectations, the company guided full year 2013 earnings outlook below Street.

Profit from continuing operations grew 14% to $236 million for the fourth quarter. Adjusted earnings from continuing operations rose to $255 million or $0.73 per share from $214 million or $0.60 per share.

Revenue remained flat at $26.76 billion. Analysts, on average, had expected a profit of $0.72 per share on revenue of $27.25 billion for the fourth quarter.

Revenue for the Pharmaceutical segment declined 1% to $24.3 billion, primarily due to brand-to-generic conversions. Segment profit grew 15% to $354 million, on strong performance of generic programs and the benefits of expanded business with new and existing customers.

Revenue for the Medical segment increased 5% to $2.4 billion. Segment profit rose 2% to $79 million, primarily driven by increased sales of preferred products, offset by expenses related to the new systems implementation.

Return on equity rose to 15.1% from 14.1%, while adjusted return on equity increased to 16.3% from 14.9%. Net debt to capital for the quarter remained unchanged at 9%.

Looking ahead into the fiscal 2013, the company expects adjusted earnings from continuing operations of $3.35 to $3.50 per share, while Street predicts $3.55 per share. The outlook incorporates the previously announced non-renewal of the Express Scripts (NASDAQ:ESRX) contract.

CAH closed Wednesday's regular session down 1.30% at $42.53. The stock has been trading between $37.53 and $46.23 for the past 52 weeks.


Rich
i On The Market - Daily Newsletter
Every trading day, be ready to attack the market instead of reacting to the market.

You will know where the key technical resistance and support levels are and what the market is likely to do next. iStock will arm you with a target list of stocks to buy and sell - right now - based on our exclusive, proprietary trading models.

Two Week FREE Trial


Signup for i on the market daily edition


Advertisement

Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

Advertisement
Connect with iStockAnalyst
Popular Articles
Recent Research and Quote
Advertisement
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.